IBAB Ion Beam Applications SA

IBA – Share buyback

IBA – Share buyback



Louvain-la-Neuve, Belgium, March 24th, 2025 - Ion Beam Applications SA (IBA) announces today the launch of a share buyback program, effective as of March 25th, 2025, in application of article 7:215 of the Belgian Companies and Associations Code.

By a decision of the Board of Directors of March 18th, 2025, taken pursuant to the authorization given by the EGM of September 4th, 2023, IBA launched a program to buy back own shares through a mandate given to a market intermediary. This program covers a maximum of 650.000 ordinary shares. Depending on market conditions, it will be executed over a fixed period of time from March 25th, 2025, to December 31st, 2025 (included). Its objective is to cover the company’s obligation of shares delivery as part of long-term incentive plans granted to management and certain employees in the form of stock options.

IBA will continuously monitor its current and future obligations under its incentive plans in order to maintain an adequate level of treasury shares.

The number of treasury shares held by IBA amounted to 313.579 on March 24th, 2025. The total number of IBA ordinary shares outstanding is 30.282.218.

***ENDS***

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

CONTACT

Olivier Lechien

Corporate Communication Director



Attachment



EN
24/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

 PRESS RELEASE

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, September 10, 2025 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 3, 2025. In its notification, Marcel Jo Maschmeyer ind...

 PRESS RELEASE

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 10 septembre 2025, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notification reçu...

Michiel Declercq
  • Michiel Declercq

IBA 1H25 Conference call feedback & model update

IBA reported good 1H25 results, with revenues up 40% to € 304.9m (kbcse: € 274.6m) driven by strong backlog conversion in PT as well as OA. However, as most of the conversion relates to legacy lower margin contracts in Spain and China, the gross profit increase of +27% to € 90.0m (kbcse: € 93.4m) and REBIT of € 10.6m (kbcse: € 10.3m) were broadly in line with our estimates. However net cash significantly deteriorated on the back of WC investments, as anticipated. We are pleased to see IBA reiter...

ING Helpdesk
  • ING Helpdesk

REVISED VERSION - Benelux Morning Notes - updated to include IBA news

CFE: 1H results a bit light, FY outlook maintained. CMB.TECH: VLCC reasonable, pressure on Dry Bulk rates. dsm-firmenich: Givaudan CMD; Strategy 2030. Gimv: Investing in specialised healthcare services in the Netherlands. IBA: More sales but at lower margin

Hilde Van Boxstael ... (+6)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Lewi

ResearchPool Subscriptions

Get the most out of your insights

Get in touch